SCHEMBL13839396

SCHEMBL13839396

CSc1nc(N)c2c([N+](=O)[O-])cn(C3O[C@H](COC(C)=O)[C@@H](OC(C)C)[C@@]3(C)OC(C)=O)c2n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13650036 0.93 LMNA (0.30) —
SCHEMBL13650025 0.84 ALDH1A1 (0.33) —
SCHEMBL13725076 0.81 LMNA (0.33) —
SCHEMBL13650028 0.80 — —
SCHEMBL13726434 0.80 — —
SCHEMBL13839391 0.79 — —
SCHEMBL13725452 0.79 — —
SCHEMBL14081712 0.79 ADK (0.35) —
SCHEMBL4014575 0.79 ADK (0.35) —
SCHEMBL13870386 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534771-B2 Tricyclic-nucleoside prodrugs for treating viral infections SMITHKLINE BEECHAM CORPORATION (US) 2009-05-19 — — US disclosed
Send feedback